Biologics in systemic autoimmune diseases during COVID-19 pandemic

Clin Rheumatol. 2020 Dec;39(12):3529-3531. doi: 10.1007/s10067-020-05439-z. Epub 2020 Oct 4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Arthritis, Juvenile / drug therapy
  • Arthritis, Juvenile / epidemiology
  • Arthritis, Psoriatic / drug therapy
  • Arthritis, Psoriatic / epidemiology
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / epidemiology
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / epidemiology
  • Betacoronavirus
  • Biological Products / therapeutic use*
  • COVID-19
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / epidemiology
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / mortality
  • Coronavirus Infections / therapy
  • Critical Care / statistics & numerical data*
  • Crohn Disease / drug therapy
  • Crohn Disease / epidemiology
  • Female
  • Hospitalization / statistics & numerical data*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Intubation, Intratracheal / statistics & numerical data
  • Male
  • Middle Aged
  • Mortality
  • Pandemics
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / mortality
  • Pneumonia, Viral / therapy
  • SARS-CoV-2
  • Spondylitis, Ankylosing / drug therapy
  • Spondylitis, Ankylosing / epidemiology
  • Tumor Necrosis Factor Inhibitors / therapeutic use

Substances

  • Biological Products
  • Immunosuppressive Agents
  • Tumor Necrosis Factor Inhibitors